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Abstract Our aim was to assess the ability of tocilizumab
monotherapy to reduce progressive structural joint damage
in rheumatoid arthritis patients at high risk of progression.
This study was a subanalysis from a prospective 1-year,
multicenter, X-ray-reader-blinded, randomized controlled
trial of tocilizumab [Study of Active Controlled Mono-
therapy Used for Rheumatoid Arthritis, an IL-6 Inhibitor
(SAMURAI) trial]. All patients were categorized into two
or three groups according to four independent predictive
markers for progressive joint damage [urinary C-terminal
crosslinking telopeptide (uCTX-II), urinary pyridinoline/
deoxypyridinoline (uPYD/DPD) ratio, body mass index
(BMI), and joint-space narrowing (JSN) score at baseline].
One-year progression of joint destruction was assessed in
high-risk versus low-risk groups receiving tocilizumab
monotherapy and compared with patients receiving con-
ventionaldisease-modifyingantirheumaticdrugs(DMARDs)
(n = 157 and 145, respectively). In patients at high risk
of progression of erosion as estimated by high uCTX-II,
uPYD/DPD, or low BMI, and at high risk of progression
of JSN as estimated by low BMI or high JSN score, the
52-week changes in radiological erosion and JSN, res-
pectively, were signiﬁcantly less in patients treated with
tocilizumab monotherapy compared with those receiving
DMARDs for each type of risk factor. In patients at low
risk, those receiving tocilizumab also progressed less than
those on DMARDs, although the difference did not reach
statistical signiﬁcance. Tocilizumab monotherapy is more
effective in reducing radiological progression in patients
presenting with risk factors for rapid progression than in
low-risk patients. Patients at high risk for progression may
beneﬁt more from tocilizumab treatment.
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Introduction
Biological agents targeting inﬂammatory cytokines have
proven more effective than conventional disease-modifying
antirheumatic drugs (DMARDs) for suppressing disease
activity and progressive joint damage in rheumatoid
arthritis (RA) [1–11]. Patients at high risk of progressive
joint damage who are difﬁcult to treat with conventional
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tion for treatment with biologics. Our recent studies
showed that increased urinary levels of C-terminal cross-
linked telopeptide of type II collagen (uCTX-II), total
pyridinoline/total deoxypyridinoline ratio (uPYD/DPD
ratio), joint-space narrowing (JSN) score, and low body
mass index (BMI) at baseline were all independent pre-
dictive markers for radiographically evident joint damage
in patients with RA of\5 years and treated with conven-
tional DMARDs. Although targeting patients with rapid
progression, as assessed by these predictive factors, for
treatment with biologics may be beneﬁcial, to date there is
no evidence that these agents are equally effective in such
high-risk patients. Therefore, this study aimed to investi-
gate the ability of tocilizumab monotherapy to reduce
progressive structural joint damage in high-risk patients.
Methods
Patients with RA of \5 year duration participating in a
prospective 1-year randomized controlled trial of toc-
ilizumab [Study of Active Controlled Monotherapy Used
for Rheumatoid Arthritis, an IL-6 Inhibitor (SAMURAI)
trial] [10] receiving anti-interleukin (IL)-6-receptor anti-
body monotherapy (8 mg/kg intravenously every 4 weeks,
n = 154), were categorized into two or three groups
according to their uCTX-II values, uPYD/DPD ratio, BMI,
and JSN scores at baseline (cutoff values: 500 ng/mmol
creatinine for uCTX-II, median for uPYD/DPD, 0 units for
JSN, 18.5 and 25 for BMI). These four factors were shown
to be independent predictive markers for radiographically
evident joint damage progression in 148 patients with RA
treated with conventional DMARDs in the control arm of
the SAMURAI trial [12]. Brieﬂy, this trial established that
high baseline uCTX-II, uPYD/DPD ratio and JSN score
and a low BMI were independent risk factors for pro-
gression of bone erosion as evaluated with the van der
Heijde modiﬁed Sharp method in patients with RA
receiving conventional DMARDs. In addition to these
three variables, the JSN score at baseline was also signif-
icantly associated with an increased risk of progression of
JSN score and total Sharp score (TSS). In this study, we
compared the 1-year progression of joint destruction in
these high- and low-risk groups in the two cohorts of
148 and 154 patients with RA receiving conventional
DMARDs or tocilizumab monotherapy, respectively.
SAMURAI trial
In the SAMURAI trial [10], patients were [20 years and
fulﬁlled the American College of Rheumatology (ACR;
formerly the American Rheumatism Association) 1987
revised criteria for the classiﬁcation of RA, with a disease
duration of C6 months and \5 years. In addition, they
had C6 tender joints (of 49 evaluated), C6 swollen joints
(of 46 evaluated), an erythrocyte sedimentation rate (ESR)
of C30 mm/h, and C-reactive protein (CRP) of C20 mg/l.
All patients had an inadequate response to at least one
DMARD or immunosuppressant. Use of anti-tumor necrosis
factor (anti-TNF) agents and leﬂunomide were not allowed
withinthe3 monthspriortotheﬁrstdose.Changeindoseand
type of DMARDs and/or immunosuppressants, plasma
exchangetherapies,and surgical treatmentswerenot allowed
within the previous 4 weeks. Oral corticosteroids (predniso-
loneupto10 mg/day)wereallowedifthedosagehadnotbeen
changed during the prior 2 weeks. Patients were randomly
assigned to receive either tocilizumab monotherapy at 8 mg/
kg intravenously every 4 weeks or conventional DMARD
therapy for 52 weeks. For the tocilizumab group, DMARDs
and/or immunosuppressants were discontinued from the start
of the study. Oral corticosteroids (up to 10 mg prednisolone
per day) were allowed, but the dosage could not be increased
during the study. Use of one nonsteroidal anti-inﬂammatory
drug (NSAID), including switching to another NSAID, was
allowed.FortheconventionalDMARDgroup,thedose,type,
and combination of DMARDs and/or immunosuppressants,
except for anti-TNF agents and leﬂunomide, could be varied
according to disease activity at the discretion of the treating
physician. Variations of NSAIDs and/or corticosteroids
including intra-articular corticosteroid injections were also
allowed.
Assessment of risk of radiographic progression
Posteroanterior radiographs of the hands and anteroposterior
radiographs of the feet were acquired at baseline, week 28,
and week 52 (or at the last visit for patients who withdrew
from the study prior to week 52). Radiographs were scored
using the van der Heijde modiﬁed Sharp method [13]f o r
bone erosion, JSN, and TSS independently by two readers
who were well trained and competent to score radiographs in
accordance with the method. The readers were blinded to the
treatment group and chronologic order of the images. We
measured urinary total deoxypyridinoline (uDPD) and total
pyridinoline (uPYD) by high-performance liquid chroma-
tography (HPLC) and uCTX-II by enzyme-linked immuno-
sorbent assay (ELISA) (CTX-II CartiLaps
 ELISA,
NORDIC Biosciences, Herlev, Denmark).
Statistical analysis
All statistical analyses were two-sided, and p values\0.05
were considered signiﬁcant. All statistical analyses were
carried out using SAS (SAS Institute, Cary, NC, USA
version 8.2, TS2M0).
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Groups were comparable at baseline for the risk factors
previously identiﬁed for predicting radiological progres-
sion in the DMARDs group (Table 1). As shown in Figs. 1
and 2, differences in the 1-year changes in radiological
erosion and JSN scores between patients in the DMARDs
and tocilizumab monotherapy arms varied between sub-
groups divided according to the baseline levels of each
predictive marker for radiographically evident joint dam-
age (uCTX-II, uPYD/DPD, JSN, and BMI). The 1-year
changes in radiological erosion scores in patients with high
uCTX-II, high uPYD/DPD, or low BMI at baseline, indi-
cating a high risk of progressive joint erosion, were sig-
niﬁcantly lower in tocilizumab-treated than in DMARD-
treated patients (Fig. 1). Those changes in radiological JSN
scores in patients with high uCTX-II, high uPYD/DPD,
high JSN, or low BMI at baseline, indicating a high risk of
progressive JSN, were also lower in tocilizumab-treated
than in DMARD-treated patients (Fig. 2a–d), and there
were proven to be signiﬁcant differences in cases with high
JSN and low BMI (Fig. 2c, d). In contrast, low-risk patients
receiving tocilizumab monotherapy progressed less than
patients on DMARDs, although the differences were very
smallanddidnotreachstatisticalsigniﬁcance(Figs. 1and2).
Discussion
Biological agents targeting inﬂammatory cytokines are
more effective at suppressing progression of joint damage
than are conventional DMARDs. However, previously
reported studies on the efﬁcacies of these agents for
slowing radiological damage showed that there was still
signiﬁcant progression in many patients [1–11]. These data
allowed us to recognize that many patients on nonbiologic
DMARDs show no radiographic progression, and some
even show radiographic improvement. Speciﬁcally, our
previous data showed that 39% of patients treated with
conventional DMARDs showed no radiographic progres-
sion in 1-year follow-up [10]. However, biological agents
may have side effects. With such knowledge gained from
growing experience in the use of biologics, patients would
beneﬁt from personalized therapies based on accurate
prognostic tools rather than standard therapies that do not
evaluate risk factor to guide treatment selection. A better
understanding of the prognostic factors for progressive
joint damage under nonbiological treatment and appropri-
ate targeting of biologics to patients with RA at high risk of
progressive joint damage and disability could enhance
risk–beneﬁt balance of RA therapeutic strategies. Thus,
many investigators have sought such prognostic factors.
Young-Min et al. reported the possible usefulness of
matrix metalloproteinase-3 (MMP-3) and uCTX-II in pre-
dicting radiographic outcome in RA patients treated with
DMARDs [14], and Charni et al. reported the possible
usefulness of urinary type II collagen helical peptide
(HELIX-II) [15]. We found that high baseline levels of
uCTX-II, uPYD/DPD, JSN score, and low BMI were
independently signiﬁcantly associated with 1-year pro-
gression of joint destruction under conventional DMARDs
treatment [12]. Most of these newly developed or recog-
nized markers are still not widely used in clinical practice;
however, further understanding the signiﬁcance of these
markers would facilitate better therapies. Having estab-
lished these risk factors, the efﬁcacy of biologics for
Table 1 Baseline values in the different patient groups
Variables Cutoff value DMARDs
N = 145
Tocilizumab
N = 157
N Mean of baseline value ± SD N Mean of baseline value ± SD
JSN 0 30 0 32 0
[0 115 21.1 ± 22.5 125 18.2 ± 21.8
uCTX-II (ng/mmol/creatinine) \500 53 327.2 ± 104.6 66 337.0 ± 102.9
C500 88 1249.0 ± 1014.9 83 1156.0 ± 585.8
uPYD/DPD \6.8 72 5.8 ± 0.7 76 5.5 ± 0.8
C6.8 73 8.6 ± 1.4 81 8.5 ± 1.3
BMI (kg/m
2) \18.5 20 17.5 ± 1.2 26 17.5 ± 0.6
C18.5 and\25 102 21.5 ± 1.6 102 21.5 ± 1.8
C25 21 27.1 ± 1.7 29 28.2 ± 2.4
Criteria were according to criteria of the World Health Organization [16] employees
JSN joint space narrowing, uPYD/DPD urinary pyridinoline/deoxypyridinoline ratio, uCTX-II urinary C-terminal telopeptide of type II collagen,
BMI body mass index, SD standard deviation
BMI\18.5, underweight; C18.5 and\25, normal weight; 25B, overweight or obese
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123Fig. 1 One-year change of
erosion scores in tocilizumab-
treated rheumatoid arthritis
(RA) patients at high risk for
developing erosions. One-year
change in erosion scores were
analyzed for individual risk
factors (a uCTX, b uPYD/DPD,
c BMI) at baseline. Results are
expressed as median (line across
boxes), 25–75% interquartile
range (boxes), mean (cross
symbol in boxes), standard
deviation (SD) (vertical line
across the top of the box), and
standard error (vertical line
across bottom of the box). The
ﬁlled circles represent
individual values over SD
values. Differences in changes
in erosion scores were
compared by the Wilcoxon rank
sum test. uPYD/DPD urinary
pyridinoline/deoxypyridinoline
ratio, uCTX-II urinary C-
terminal telopeptide of type II
collagen, BMI body mass index,
TCZ tocilizumab
Fig. 2 One-year change of joint
space narrowing (JSN) scores in
tocilizumab-treated rheumatoid
arthritis (RA) patients with risk
factors for developing JSN.
Score changes were analyzed
for individual risk factors
(a uCTX, b uPYD/DPD, c BMI,
d JSN) at baseline. Results are
expressed as median (line across
boxes), 25–75% interquartile
range (boxes), mean (cross
symbol in boxes), standard
deviation (SD) (vertical line
across top of the box), and
standard error (vertical line
across bottom of the box).
The ﬁlled circles represent
individual values over SD
values. Differences in change in
JSN scores were compared by
the Wilcoxon rank sum test.
uPYD/DPD urinary
pyridinoline/deoxypyridinoline
ratio, uCTX-II urinary C-
terminal telopeptide of type II
collagen, BMI body mass index,
TCZ tocilizumab
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conﬁrmed to effectively target treatment. Therefore, in this
study, subanalysis from a prospective 1-year randomized
controlled trial of tocilizumab (SAMURAI trial) was per-
formed to investigate the ability of this agent to reduce
progression of structural joint damage in high-risk patients.
There was no signiﬁcant difference in 1-year changes of
JSN scores between DMARD- and tocilizumab-treated
patients in high-risk groups, as estimated by high uCTX-II,
uPYD/DPD. Our data show, however, that tocilizumab
monotherapy effectively blocked progression of bone ero-
sion in all high-risk groups as estimated by high uCTX-II,
uPYD/DPD, or low BMI and also effectively blocked
progression of JSN in high-risk groups as estimated by low
BMI or high JSN score, The differences in 1-year changes
of erosion and JSN scores between the DMARD- and
tocilizumab-treated patients were greatest in the high-risk
groups, whereas there was little to no difference in the low-
risk group. These ﬁndings indicate that the beneﬁt of toc-
ilizumab monotherapy to inhibit bone erosion and JSN
progression is maximized in high-risk groups as estimated
by high uCTX-II, uPYD/DPD, or low BMI, and by low
BMI or high JSN score, respectively. To our knowledge,
this is the ﬁrst comprehensive report showing the useful-
ness of biomarker targeting strategies for biologics in
treating RA. There were smaller and nonsigniﬁcant dif-
ferences in 1-year changes of erosion and JSN scores
between patients in the DMARD or tocilizumab mono-
therapy treatment groups in the low-risk category, although
progression was still lower in individuals receiving toc-
ilizumab. The lack of statistical signiﬁcance can be due in
part to the very limited progression in the low-risk group
reducing the power to detect differences. These ﬁndings
also suggest that patients at low risk may beneﬁt less from
treatment with biologics unless they develop changes in
markers that indicate an increased risk of progression
during treatment with conventional DMARDs. On the
other hand, the lack of statistically signiﬁcant differences
in 1-year changes of JSN scores between patients in the
DMARDortocilizumabmonotherapytreatmentgroupsinthe
high-risk category might be due to the relatively weak prog-
nostic power of high uCTX-II and uPYD/DPD for JSN pro-
gression compared with low BMI or high JSN score [12].
Establishing means of early discrimination between
tocilizumab radiological responders and nonresponders is
therefore raised as the next issue to be addressed when
considering targeted therapeutic strategies. In conclusion,
we demonstrated that tocilizumab monotherapy is effective
in reducing radiological progression in patients presenting
with risk factors for rapid progression of joint damage.
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